FINANCE

Hong Kong Halts Cloudbreak Pharma Shares Over Suspected ‘Rigged’ IPO

Published: Sep. 11, 2026 3:55 p.m. GMT+8

00:00

00:00/00:00

Listen to this article 1x

Cloudbreak Pharma debuts on the main board of the Hong Kong Stock Exchange on July 3, 2025. Photo: VCG

Hong Kong’s securities regulator suspended trading in Cloudbreak Pharma Inc. after raising concerns that demand for the ophthalmic-drug developer’s IPO may have been artificially inflated.

The Securities and Futures Commission (SFC) said Thursday it was investigating Cloudbreak and ordered the company’s shares halted to protect investors and maintain an orderly and fair market.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS

Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.

Subscribe to both Caixin Global and Bloomberg - for the price of one.

Share this article

Open WeChat and scan the QR code

DIGEST HUB

Digest Hub

Back

Explore the story in 30 seconds

Hong Kong’s SFC suspended Cloudbreak Pharma trading over concerns its IPO demand was artificially inflated.
The July 2025 IPO raised HK$522 million; retail orders hit 78x, but shares fell 88% from the offering price.
The regulator is broadening scrutiny of Hong Kong IPO book-building and share allocations.

AI generated, for reference only

Who’s Who

AI generated, for reference only

What Happened When

2025-07：: Cloudbreak Pharma Inc. raised about HK$522 million in its IPO listing.

2025-07：: Cloudbreak's shares closed at HK$6.20, 39% below the HK$10.10 offering price on its first trading day.

2026 (earlier this year)：: Regulators focused on sponsors' oversight and their reliance on outside parties.

2026-07：: The SFC ordered Futu Securities International (Hong Kong) Ltd. to freeze as much as HK$125 million in a client account tied to an entity suspected of helping create false demand for shares in an IPO.